menu
    • menu
    [{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm \/ Not Applicable"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Isofol Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"PALADIN LABS","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"PALADIN LABS \/ Paladin Labs","highestDevelopmentStatusID":"10","companyTruncated":"PALADIN LABS \/ Paladin Labs"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","graph1":"Urology","graph2":"Approved","graph3":"Endo Pharm","amount2":0.54000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0.54000000000000004,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Endo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm \/ Endo Pharmaceuticals"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Endo International","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"PALADIN LABS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PALADIN LABS \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"PALADIN LABS \/ Endo International"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Petros Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Endo Pharm \/ Auxilium Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm \/ Auxilium Pharmaceuticals"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Posaconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm \/ Not Applicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"IRELAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tiopronin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm \/ Not Applicable"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Calcipotriol","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Endo Pharm \/ Endo Pharm","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm \/ Endo Pharm"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Endo Pharm

    Menu

    Endo Pharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            John Elway Partners with Endo to Promote XIAFLEX® for Dupuytren's Contracture

                            Details : Xiaflex (collagenase clostridium histolyticum) is a collagenase enzyme used to promote debridement of necrotic tissue in burns and skin ulcers. It is indicated for Dupuytren's Contracture treatment.

                            Brand Name : Xiaflex

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 20, 2024

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : MC2 Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada

                            Details : The agreement aims to commercialize Wynzora Cream, a combination of calcipotriene and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis, in Canada.

                            Brand Name : Wynzora

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 15, 2024

                            Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : MC2 Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiopronin

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Launches Tiopronin Delayed-Release Tablets, Generic Version of THIOLA EC®

                            Details : Thiola EC-Generic (tiopronin) is a reducing & cystine-binding thiol drug, which is indicated to help prevent the formation of one type (cystine) of kidney stones in certain adult & pediatric patients.

                            Brand Name : Thiola EC-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 15, 2024

                            Lead Product(s) : Tiopronin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Posaconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

                            Details : Posaconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible for the conversion of lanosterol to ergosterol in the fungal...

                            Brand Name : Noxafil-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 03, 2023

                            Lead Product(s) : Posaconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avanafil

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Recipient : Petros Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erec...

                            Details : STENDRA (avanafil), an oral phosphodiesterase 5 (PDE5) inhibitor for treatment of erectile dysfunction, provides positive results from its OTC draft label comprehension study for its ED drug demonstrated understanding of the messages therein.

                            Brand Name : Stendra

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 19, 2022

                            Lead Product(s) : Avanafil

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Recipient : Petros Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PALADIN LABS

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            PALADIN LABS

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Endo International

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada

                            Details : Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities relat...

                            Brand Name : BA058

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 05, 2021

                            Lead Product(s) : Abaloparatide Acetate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Endo International

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Urology

                            Study Phase : Approved

                            Recipient : BioSpecifics

                            Deal Size : $540.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Endo Completes Acquisition of BioSpecifics

                            Details : BioSpecifics received a royalty stream from Endo related to Endo's collagenase-based therapies, which currently include XIAFLEX, marketed by Endo Pharmaceuticals.

                            Brand Name : Xiaflex

                            Molecule Type : Large molecule

                            Upfront Cash : $540.0 million

                            December 02, 2020

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Urology

                            Highest Development Status : Approved

                            Recipient : BioSpecifics

                            Deal Size : $540.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            PALADIN LABS

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            PALADIN LABS

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arfolitixorin,Oxaliplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Isofol Medical

                            Deal Size : $100.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Isofol Announces Licensing Agreement for Paladin Labs Inc. To Commercialize Arfolitixorin in Canada

                            Details : The license agreement is initially focused on the development and commercialization of arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Japan, which is projected to be the second largest addressable patient market...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $103.0 million

                            November 02, 2020

                            Lead Product(s) : Arfolitixorin,Oxaliplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Isofol Medical

                            Deal Size : $100.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo to Present Qwo™ (Collagenase Clostridium Histolyticum-Aaes) Data at Vegas Cosmetic Surgery & Aesthetic ...

                            Details : Endo International plc presentation will include a general overview of collagenase clostridium histolyticum-aaes and will review data from the product's phase 3 pooled trial analyses.

                            Brand Name : Qwo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 24, 2020

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth